Reason for request
Inclusion on list of products reimbursed by National Insurance and for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of FIRMAGON is substantial. |
Clinical Added Value
| no clinical added value |
In the context of the current strategy for treatment of advanced prostate cancer, with a combination of a Gn-RH analogue and an antiandrogen in the first month of treatment, FIRMAGON provides no improvement in actual benefit (IAB level V). |
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
h7HHVmdydagM9Fk4
